Artgen Biotech PJSC (MOEX:ISKJ)
Russia · Delayed Price · Currency is RUB 59.54
+0.84 (1.43%)
At close: Jul 8, 2022
Artgen Biotech PJSC Income Statement
Financials in millions RUB. Fiscal year is January - December.
Millions RUB. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,716 | 1,521 | 1,369 | 1,137 | 1,181 | |
Revenue Growth (YoY) | 12.80% | 11.18% | 20.38% | -3.72% | 8.93% |
Cost of Revenue | 612.04 | 439.3 | 394.47 | 466.57 | 461.39 |
Gross Profit | 1,104 | 1,082 | 974.09 | 670.34 | 719.4 |
Selling, General & Admin | 830.16 | 697.86 | 627.83 | 504.82 | 496.52 |
Amortization of Goodwill & Intangibles | 72.59 | 20.84 | 19.39 | 13.89 | 13.75 |
Other Operating Expenses | - | - | - | 14.58 | 11.19 |
Operating Expenses | 972.24 | 782.57 | 698.73 | 572.88 | 588.98 |
Operating Income | 131.9 | 299.62 | 275.36 | 97.46 | 130.42 |
Interest Expense | -89.76 | -95.06 | -49.23 | -67.81 | -50.68 |
Interest & Investment Income | 102.38 | 75.42 | 32.33 | 12.48 | 6.23 |
Earnings From Equity Investments | -25.97 | -3.5 | -24.17 | 23.14 | -5.21 |
Currency Exchange Gain (Loss) | 1.69 | -5.38 | 2.02 | -3.36 | -1.24 |
Other Non Operating Income (Expenses) | -4.39 | -53.51 | -22.17 | -6.46 | -33.11 |
EBT Excluding Unusual Items | 115.85 | 217.59 | 214.13 | 55.45 | 46.42 |
Gain (Loss) on Sale of Investments | 14.6 | 16.15 | -1.4 | - | - |
Gain (Loss) on Sale of Assets | -0.24 | -11.27 | -1.34 | -20.63 | -1.69 |
Asset Writedown | -44.73 | -5.04 | - | -5.52 | -9.28 |
Other Unusual Items | - | - | - | - | -5.98 |
Pretax Income | 85.48 | 217.43 | 211.39 | 29.31 | 29.46 |
Income Tax Expense | -22.2 | -23.74 | 16.74 | 6.23 | -4.09 |
Earnings From Continuing Operations | 107.68 | 241.16 | 194.66 | 23.08 | 33.55 |
Minority Interest in Earnings | -10.73 | -26.25 | -25.8 | 23.04 | -21.92 |
Net Income | 96.95 | 214.91 | 168.86 | 46.12 | 11.63 |
Net Income to Common | 96.95 | 214.91 | 168.86 | 46.12 | 11.63 |
Net Income Growth | -54.89% | 27.27% | 266.14% | 296.51% | -84.04% |
Shares Outstanding (Basic) | 74 | 74 | 93 | 87 | 80 |
Shares Outstanding (Diluted) | 75 | 74 | 93 | 87 | 80 |
Shares Change (YoY) | 0.89% | -19.64% | 6.60% | 8.64% | 6.67% |
EPS (Basic) | 1.31 | 2.91 | 1.82 | 0.53 | 0.15 |
EPS (Diluted) | 1.29 | 2.89 | 1.82 | 0.53 | 0.15 |
EPS Growth | -55.36% | 58.79% | 243.40% | 264.54% | -85.01% |
Free Cash Flow | 20.36 | 382.16 | 230.56 | 84.37 | 127.51 |
Free Cash Flow Per Share | 0.27 | 5.13 | 2.49 | 0.97 | 1.59 |
Dividend Per Share | - | - | 1.200 | 1.000 | - |
Dividend Growth | - | - | 20.00% | - | - |
Gross Margin | 64.34% | 71.13% | 71.18% | 58.96% | 60.92% |
Operating Margin | 7.69% | 19.69% | 20.12% | 8.57% | 11.04% |
Profit Margin | 5.65% | 14.12% | 12.34% | 4.06% | 0.98% |
Free Cash Flow Margin | 1.19% | 25.12% | 16.85% | 7.42% | 10.80% |
EBITDA | 225.27 | 354.51 | 324.52 | 137.5 | 188.79 |
EBITDA Margin | 13.13% | 23.30% | 23.71% | 12.09% | 15.99% |
D&A For EBITDA | 93.37 | 54.89 | 49.16 | 40.05 | 58.37 |
EBIT | 131.9 | 299.62 | 275.36 | 97.46 | 130.42 |
EBIT Margin | 7.69% | 19.69% | 20.12% | 8.57% | 11.04% |
Effective Tax Rate | - | - | 7.92% | 21.26% | - |
Revenue as Reported | 1,716 | 1,521 | 1,369 | 1,137 | 1,181 |
Advertising Expenses | 94.67 | 98.43 | 95.94 | 72.46 | 61.87 |